Review of NICE Technology Appraisal Guidance No. 212; Bevacizumab in combination with oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine for treating metastatic colorectal cancer.

The Institute was proposing that TA212 should be moved to the static list as there is no new evidence that is likely to have a material effect on the existing recommendations.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

TA212 will consequently be moved to the static list. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

July 2013